I found this interesting article about using Ambroxol, a well-established mucolytic agent and expectorant used to treat respiratory diseases associated with thick, viscous, or excessive mucus, to fight Parkinson’s: Ambroxol as a Treatment for Parkinson Disease Dementia
You can read it here.
This randomized clinical trial published in JAMA Neurology investigated whether Ambroxol (a common expectorant) could serve as a disease-modifying treatment for Parkinson Disease Dementia (PDD).
Key Findings
- Safety & Tolerability: The study found that high-dose Ambroxol (1050 mg/day) is safe and well-tolerated in patients with PDD over a 52-week period. The most common side effects were mild gastrointestinal issues.
- Target Engagement: The drug successfully crossed the blood-brain barrier and reached the intended target. It acted as a “chaperone” to increase levels of β-glucocerebrosidase (GCase), an enzyme often deficient in Parkinson’s patients (especially those with GBA1 gene mutations).
- Cognitive Results: Despite the successful biological “target engagement,” the study did not find a significant improvement in cognitive scores (measured by ADAS-Cog-13) compared to the placebo group over the one-year duration.
- Neuropsychiatric Benefits: Interestingly, patients on the placebo showed worsening neuropsychiatric symptoms, while those taking Ambroxol remained stable, suggesting a potential protective effect on mood and behavior.
Why This Matters:
While the trial didn’t “cure” cognitive decline in a year, it proved that the drug does exactly what it’s supposed to do biologically. Researchers noted that a 12-month study might be too short to see major cognitive changes and suggested that future trials should focus specifically on GBA1 mutation carriers and use more sensitive testing tools.